Usca Ria LLC lifted its stake in shares of CVS Health Corp (NYSE:CVS) by 18.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,310 shares of the pharmacy operator’s stock after purchasing an additional 7,713 shares during the period. Usca Ria LLC’s holdings in CVS Health Corp were worth $4,048,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. First Trust Advisors LP raised its stake in CVS Health Corp by 34.8% in the 1st quarter. First Trust Advisors LP now owns 739,753 shares of the pharmacy operator’s stock valued at $58,071,000 after acquiring an additional 190,893 shares during the period. Meridian Management Co. raised its stake in CVS Health Corp by 19.0% in the 1st quarter. Meridian Management Co. now owns 24,585 shares of the pharmacy operator’s stock valued at $1,930,000 after acquiring an additional 3,925 shares during the period. Investment Management of Virginia LLC raised its stake in CVS Health Corp by 41.2% in the 1st quarter. Investment Management of Virginia LLC now owns 33,060 shares of the pharmacy operator’s stock valued at $2,595,000 after acquiring an additional 9,651 shares during the period. Copeland Capital Management LLC raised its stake in CVS Health Corp by 244.3% in the 1st quarter. Copeland Capital Management LLC now owns 105,559 shares of the pharmacy operator’s stock valued at $8,553,000 after acquiring an additional 74,896 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its stake in CVS Health Corp by 4.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 393,629 shares of the pharmacy operator’s stock valued at $31,093,000 after acquiring an additional 16,525 shares during the period. Institutional investors own 81.64% of the company’s stock.
A number of equities research analysts recently weighed in on the company. Robert W. Baird restated a “hold” rating and issued a $77.00 price target on shares of CVS Health Corp in a research note on Friday, October 27th. Citigroup Inc dropped their price target on CVS Health Corp from $87.00 to $74.00 and set a “neutral” rating on the stock in a research note on Friday. Cowen and Company set a $86.00 price objective on CVS Health Corp and gave the company a “buy” rating in a report on Sunday, October 29th. BidaskClub raised CVS Health Corp from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, TheStreet lowered CVS Health Corp from a “b-” rating to a “c+” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $87.33.
In other CVS Health Corp news, EVP Thomas M. Moriarty sold 90,267 shares of the stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $79.61, for a total value of $7,186,155.87. Following the completion of the transaction, the executive vice president now directly owns 70,102 shares in the company, valued at $5,580,820.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jonathan C. Roberts sold 85,743 shares of the stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $83.14, for a total value of $7,128,673.02. Following the completion of the transaction, the chief operating officer now owns 119,555 shares of the company’s stock, valued at $9,939,802.70. The disclosure for this sale can be found here. Insiders sold 716,625 shares of company stock valued at $58,318,431 over the last quarter. Corporate insiders own 0.61% of the company’s stock.
CVS Health Corp (NYSE:CVS) opened at $69.25 on Friday. The company has a market capitalization of $70.40 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 1.26 and a beta of 0.86. CVS Health Corp has a 1 year low of $68.01 and a 1 year high of $84.89. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.09 and a quick ratio of 0.56.
CVS Health Corp (NYSE:CVS) last posted its earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 EPS for the quarter, beating the consensus estimate of $1.31 by $0.02. The firm had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.36 billion. CVS Health Corp had a return on equity of 17.47% and a net margin of 2.93%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company earned $1.32 earnings per share. equities research analysts anticipate that CVS Health Corp will post 5.88 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th were given a $0.50 dividend. The ex-dividend date was Monday, October 23rd. This represents a $2.00 annualized dividend and a yield of 2.89%. CVS Health Corp’s dividend payout ratio is presently 39.84%.
CVS Health Corp Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
What are top analysts saying about CVS Health Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CVS Health Corp and related companies.